Avibactam

beta Lactamase Inhibitor

Key facts

Avibactam is an onp drug in the beta Lactamase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as beta Lactamase Inhibitors. DrugCentral lists 9 molecular targets, including bla; blaT-3; blaT-4;, blaUOE-1 and ampC. Recorded indications include Bacterial urinary infection, Infectious disease of abdomen and Pyelonephritis.

• Approval status: onp (first approved 2015 by the FDA).
• Drug class: beta Lactamase Inhibitor.
• Mechanism of action: beta Lactamase Inhibitors.
• Molecular targets: bla; blaT-3; blaT-4;, blaUOE-1, ampC and blaKPC-2 (9 listed in DrugCentral).
• Indications: Bacterial urinary infection, Infectious disease of abdomen and Pyelonephritis.
• Molecular formula: C7H11N3O6S; molecular weight 265.24 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Bacterial urinary infection
• Infectious disease of abdomen
• Pyelonephritis

Mechanism & targets

• Mechanism of action (MoA): beta Lactamase Inhibitors
• Established pharmacologic class: beta Lactamase Inhibitor

Molecular targets (9)

Target	Gene	Action	Activity
Beta-lactamase TEM	bla; blaT-3; blaT-4;	unknown	IC50 8.72
Beta-lactamase	blaUOE-1	inhibitor	Kd 8.70
Beta-lactamase	ampC	inhibitor	Kd 8.15
Beta-lactamase	blaKPC-2	unknown	Ki 7.96
Beta-lactamase OXA-1	bla	unknown	IC50 6.89
Carbepenem-hydrolyzing beta-lactamase KPC	bla	unknown	IC50 6.73
Penicillin-binding protein 2	mrdA	unknown	IC50 6.23
Beta-lactamase	ampC	inhibitor	Kd 6.18
Beta-lactamase	ari-1	unknown	Ki 5.77

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2015-02-25	FDA	—	CEREXA INC

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	69.0

Chemical structure

• Molecular formula: C₇H₁₁N₃O₆S
• Molecular weight: 265.24 g/mol
• CAS number: 1192500-31-4
• InChIKey: NDCUAPJVLWFHHB-UHNVWZDZSA-N
• PubChem CID: 9835049

NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Avibactam used for?

DrugCentral lists the following indications for Avibactam: Bacterial urinary infection, Infectious disease of abdomen and Pyelonephritis.

How does Avibactam work?

Avibactam is classified as beta Lactamase Inhibitors; its molecular targets in DrugCentral include bla; blaT-3; blaT-4;, blaUOE-1 (inhibitor), ampC (inhibitor) and blaKPC-2.

When was Avibactam first approved?

Avibactam was first approved by the FDA in 2015.

What drug class does Avibactam belong to?

Avibactam is in the beta Lactamase Inhibitor class.

What is the chemical formula of Avibactam?

Avibactam has the molecular formula C7H11N3O6S and a molecular weight of 265.24 g/mol.

Sources

• DrugCentral drug card 4946 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1689063 — compound record and bioactivity
• PubChem CID 9835049 — chemical identifiers
• DrugBank DB09060 — drug record
• FDA UNII 7352665165 — substance identity
• DailyMed: FDA labels for Avibactam — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.